Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-22T13:49:49.103Z Has data issue: false hasContentIssue false

Perampanel-Induced Cataplexy in a Young Male with Generalized Epilepsy

Published online by Cambridge University Press:  10 May 2021

Kelsey Kenaan
Affiliation:
Children’s Hospital of Wisconsin, Milwaukee, WI, USA
Mohsin Zafar
Affiliation:
Orange Park Medical Center, Department of Psychiatry, Jacksonville, FL, USA
Ronnie Bond
Affiliation:
Orange Park Medical Center, Department of Neurology, Jacksonville, FL, USA
Barbara Gracious
Affiliation:
Orange Park Medical Center, Department of Psychiatry, Jacksonville, FL, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Perampanel is an anti-epileptic drug reported to exert its effects in the central never system (CNS) by inhibiting post-synaptic glutamate receptors. The most commonly reported neuropsychiatric side effects are affective dysregulation with some reports of psychosis. However, the precise therapeutic mechanism is unknown. We report on a 32-year-old African American male with recurring generalized tonic-clonic (GTC) seizures, who presented to our hospital with onset of mood lability for several months, subsequent to adding perampanel to his antiepileptic medications. On presentation, perampanel administration was temporarily withheld, and subsequently, noted to be coincident with neuropsychiatric symptomatology, including motor weakness in emotional contexts. The mechanisms underlying cataplexy are complex and, in our patient, most likely induced by an interaction between perampanel and the wakeful inhibition of the sublaterodorsal nucleus projections.

Type
Abstracts
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Footnotes

Presenting Author: Mohsin Zafar